Evidence map›Paper›PMID 34071479›Full record

ReviewMolecules (Basel, Switzerland)2021

Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator.

Denise Bellotti, Maurizio Remelli

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 143 citations in OpenAlex.

  1. Article
  2. Siderophore-metal complexes in Paraburkholderia phymatum: structure elucidation of phymabactin.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  3. Data-driven optimization of siderophore fermentation byApplied and environmental microbiology · 2026
    Article
  4. Article
  5. Article
  6. TheEuropean journal of nuclear medicine and molecular imaging · 2026
    Observational
  7. Article
  8. Article
  9. Biology of novel LpxC inhibitors forMicrobiology spectrum · 2026
    Article
  10. Article
  11. Article
  12. Transmetalation in Cancer Pharmacology.International journal of molecular sciences · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Denise BellottiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44100 Ferrara, Italy.ORCID 0000-0002-2634-0228
Maurizio RemelliDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44100 Ferrara, Italy.ORCID 0000-0002-5705-3352
University of Ferrara · IT

Funding

Università degli Studi di Ferrara FAR 2020
6 · The paper itself

Abstract

Deferoxamine B is an outstanding molecule which has been widely studied in the past decade for its ability to bind iron and many other metal ions. The versatility of this metal chelator makes it suitable for a number of medicinal and analytical applications, from the well-known iron chelation therapy to the most recent use in sensor devices. The three bidentate hydroxamic functional groups of deferoxamine B are the centerpiece of its metal binding ability, which allows the formation of stable complexes with many transition, lanthanoid and actinoid metal ions. In addition to the ferric ion, in fact, more than 20 different metal complexes of deferoxamine b have been characterized in terms of their chemical speciation in solution. In addition, the availability of a terminal amino group, most often not involved in complexation, opens the way to deferoxamine B modification and functionalization. This review aims to collect and summarize the available data concerning the complex-formation equilibria in solutions of deferoxamine B with different metal ions. A general overview of the progress of its applications over the past decade is also discussed, including the treatment of iron overload-associated diseases, its clinical use against cancer and neurodegenerative disorders and its role as a diagnostic tool.

Indexed as

AnimalsAntineoplastic AgentsChelating AgentsChemistry, PharmaceuticalCOVID-19 Drug TreatmentDeferoxamineElectrochemistryElectrolytesHumansHydrogen-Ion ConcentrationIonsIronIron Chelating AgentsIron OverloadKineticsLigandsAntineoplastic AgentsChelating AgentsDeferoxamineElectrolytesIonsIronIron Chelating AgentsLigandsMetalsZirconiumchelation therapydeferoxamine B (DFOB)metal complexessolution equilibria

Identifiers

PMID34071479
PMCPMC8198152
OpenAlexW3164637940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.